Hetlioz tasimelteon regulatory update

Vanda said EMA accepted for review an MAA for Hetlioz tasimelteon to treat non-24 hour sleep wake disorder. FDA approved the melatonin MT1 and MT2 receptor agonist in January. The product has Orphan D...